Loading...
XSHE002793
Market cap541mUSD
Jan 10, Last price  
3.74CNY
1D
-7.43%
1Q
-9.88%
Jan 2017
-79.79%
IPO
-29.21%
Name

Luoxin Pharmaceuticals Group Stock Co Ltd

Chart & Performance

D1W1MN
XSHE:002793 chart
P/E
—
P/S
1.68
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
20.37%
Revenues
2.36b
-34.11%
423,429,578474,636,960474,174,427537,325,776584,211,860637,397,258828,044,036935,445,8207,588,790,5766,095,945,5676,477,932,5903,587,547,0402,363,867,226
Net income
-661m
32,521,06953,666,21545,964,13463,959,35281,787,382100,362,781115,851,719111,345,642633,950,170320,700,649406,096,2230-661,138,090
CFO
553m
46,531,65233,314,99964,752,39341,830,87958,122,83072,742,004102,274,961114,115,186116,330,2610120,632,9550552,791,495
Dividend
May 13, 20220.03 CNY/sh
Earnings
May 16, 2025

Profile

Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers medical treatment and health services. The company was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. Luoxin Pharmaceuticals Group Stock Co., Ltd. is based in Linyi, China.
URL
http://www.luoxin.cn/
IPO date
Apr 15, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,363,867
-34.11%
3,587,547
-44.62%
Cost of revenue
2,554,593
4,687,593
Unusual Expense (Income)
NOPBT
(190,726)
(1,100,046)
NOPBT Margin
Operating Taxes
164,806
Tax Rate
NOPAT
(355,532)
(1,100,046)
Net income
(661,138)
 
Dividends
(14,947)
Dividend yield
0.14%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
555,603
3,264,849
Long-term debt
534,399
316,693
Deferred revenue
89,934
93,581
Other long-term liabilities
151,551
79,137
Net debt
25,454
1,915,776
Cash flow
Cash from operating activities
552,791
CAPEX
(242,390)
Cash from investing activities
906,959
Cash from financing activities
(1,716,343)
384,978
FCF
1,940,861
(398,013)
Balance
Cash
694,999
1,450,905
Long term investments
369,549
214,861
Excess cash
946,355
1,486,388
Stockholders' equity
2,105,988
2,798,269
Invested Capital
2,801,515
5,488,872
ROIC
ROCE
EV
Common stock shares outstanding
1,083,833
1,425,048
Price
5.36
-30.12%
7.67
-25.81%
Market cap
5,809,345
-46.85%
10,930,118
-27.54%
EV
5,937,306
12,978,266
EBITDA
31,816
(868,740)
EV/EBITDA
186.61
Interest
75,973
122,672
Interest/NOPBT